Number of subjects	Pooled relative risk (95% CI)	Pooled absolute risk difference (95% CI)	Number needed to treat (95%CI)	Attributable events/1000 treated (95% Cl)	Evidence
	-				
3,746	0.94 (0.89; 1.00)	-0.04 (-0.08; 0.00)	-25 (-452; -13)	-40 (-78; -2)	Insufficient
245	Significant reduction in severity and pad utilization				Low
158	NS differences				Insufficient
108	NS differences				Insufficient
27	NS differences				Insufficient
159	0.63 (0.49; 0.80)	-0.30 (-0.44; -0.16)	-3 (-6; -2)	-297 (-438; -157)	Insufficient
338	0.17 (0.06; 0.44)	-0.11 (-0.18; -0.05)	-9 (-22; -6)	-112 (-178; -46)	Insufficient
				-	
158					
NS differences					Insufficient
in UI					
0					Insufficient
	NS differences in LUU				Insufficient
CO	NS differences in UUI				insuncient
201					
	NS differences in UUI				Low
• • • • •	subjects 3,746 245 158 108 27 159 338 158 NS differences in UI 164 Significant reduction in stress, urgency, but not mixed UI 85	Number of subjectsrisk (95% Cl)3,7460.94 (0.89; 1.00)245Significant reduction in severity and pad utilization245Significant reduction in severity and pad utilization158NS differences1590.63 (0.49; 0.80)3380.17 (0.06; 0.44)164Significant reduction in stress, urgency, but not mixed UI85NS differences in UUI	Number of subjectsrisk (95% CI)risk difference (95% CI)3,7460.94 (0.89; 1.00)-0.04 (-0.08; 0.00)245Significant reduction in severity and pad utilization-0.04 (-0.08; 0.00)1245NS ginificant reduction in severity and pad utilization-0.04 (-0.08; 0.00)158NS differences-108NS differences-108NS differences-1090.63 (0.49; 0.80)-0.30 (-0.44; -0.16)3380.17 (0.06; 0.44)-0.11 (-0.18; -0.05)158NS differences in UI-164Significant reduction in stress, urgency, but not mixed UINS differences in UUI85NS differences in UUI	Number of subjects  risk (95% Cl)  risk difference (95% Cl)  to treat (95% Cl)    3,746  0.94 (0.89; 1.00)  -0.04 (-0.08; 0.00)  -25 (-452; -13)    245  Significant reduction in severity and pad utilization	Number of subjects  risk (95% CI)  risk difference (95% CI)  to treat (95% CI)  events/1000 treated (95% CI)    3,746  0.94 (0.89; 1.00)  -0.04 (-0.08; 0.00)  -25 (-452; -13)  -40 (-78; -2)    245  Significant reduction in severity and pad utilization

## Appendix Table F100. Clinical outcomes after nonpharmacological treatments compared to no active treatment

Studies reference	Number of subjects	Pooled relative risk (95% CI)	Pooled absolute risk difference (95% Cl)	Number needed to treat (95%Cl)	Attributable events/1000 treated (95% CI)	Evidence
<b>Vaginal cones</b> (1 study) Williams, 2006 <sup>615</sup>	159	NS differences				Insufficien
Weight loss (1 study) Brown, 2006 <sup>502</sup>	1319 NS change in urgency UI	0.85 (0.73; 0.99)	-0.05 (-0.11; 0.00)	-18 (-329; -10)	-54 (-105; -3)	Insufficien
Diet high in soy protein (1 study)	36					
Manonai, 2006 <sup>566</sup>	Significant increase in stress UI, NS changes in urgency UI					Insufficien
ADVERSE EFFECTS			-			
<b>Macroplastique</b> (1 study) Ghoniem, 2009 <sup>533</sup>	240	NS differences				Insufficien